Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 178

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 178
---
’s product candidates, if approved; |

| • |     | meeting milestones for licensed programs; |

| • |     | successful commercial launch following any marketing approval, including the development of a commercial infrastructure, whether in-house or with one or more collaborators; |

| • |     | a continued acceptable safety profile following any marketing approval of Kineta’s product candidates; |

| • |     | commercial acceptance of Kineta’s product candidates by patients, the medical community and third-party payors; |

| • |     | satisfying any required post-marketing approval commitments to applicable regulatory authorities; |

| • |     | identifying, assessing and developing new product candidates from Kineta’s development platform; |

| • |     | obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally; |

| • |     | defending against third-party interference or infringement claims, if any; |

| • |     | entering into, on favorable terms, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize Kineta’s product candidates; |

| • |     | obtaining coverage and adequate reimbursement by third-party payors for Kineta’s product candidates; |

| • |     | addressing any competing therapies and technological and market developments; and |

| • |     | attracting, hiring and retaining qualified personnel. |

Kineta may never be successful in achieving its objectives and, even if it does, may never generate revenue that is significant or large enough to achieve profitability. If Kineta does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis. Kineta’s failure to become and remain profitable would decrease the value of the Company and could impair its ability to maintain or further its research and development efforts, raise additional necessary capital, grow its business and continue its operations. Kineta will need to obtain substantial additional funding to complete the development and commercialization of its product candidates. If Kineta is unable to raise this capital when needed, Kineta may be forced to delay, reduce or eliminate its product development programs or other operations. Since its inception, Kineta has used substantial amounts of cash to fund its operations and expects its expenses to increase substantially during the next few years. The development of biopharmaceutical product candidates, especially immuno-oncology product candidates, is capital intensive. As Kineta’s product candidates enter and advance through preclinical studies and clinical trials, Kineta will need substantial additional funds to expand its clinical